CN107158012A - Application of the Morinda officinalis FOS extract in preventing and treating Alzheimer disease drug, health products or food is prepared - Google Patents
Application of the Morinda officinalis FOS extract in preventing and treating Alzheimer disease drug, health products or food is prepared Download PDFInfo
- Publication number
- CN107158012A CN107158012A CN201710411670.6A CN201710411670A CN107158012A CN 107158012 A CN107158012 A CN 107158012A CN 201710411670 A CN201710411670 A CN 201710411670A CN 107158012 A CN107158012 A CN 107158012A
- Authority
- CN
- China
- Prior art keywords
- morinda officinalis
- fos
- extract
- treating alzheimer
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000096284 Gynochthodes officinalis Species 0.000 title claims abstract description 67
- 239000000284 extract Substances 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 26
- 229940079593 drug Drugs 0.000 title claims abstract description 18
- 235000013305 food Nutrition 0.000 title claims abstract description 15
- 230000036541 health Effects 0.000 title claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000012141 concentrate Substances 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 11
- 239000012043 crude product Substances 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 8
- 238000005057 refrigeration Methods 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000003957 anion exchange resin Substances 0.000 claims description 5
- 238000000967 suction filtration Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000012869 ethanol precipitation Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000001226 reprecipitation Methods 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 17
- 230000013016 learning Effects 0.000 abstract description 8
- 230000015654 memory Effects 0.000 abstract description 7
- 206010039966 Senile dementia Diseases 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 4
- 230000007059 acute toxicity Effects 0.000 abstract description 2
- 231100000403 acute toxicity Toxicity 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 7
- 230000032683 aging Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 102000013498 tau Proteins Human genes 0.000 description 4
- 108010026424 tau Proteins Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000157491 Morinda Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001465805 Nymphalidae Species 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000017524 noni Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of the Morinda officinalis FOS extract in preventing and treating Alzheimer disease drug, health products or food is prepared, the present invention is studied through interior animal experiment and found, Morinda officinalis FOS extract can significantly improve A β1‑42Cause to intend Senile Dementia Model Rats ability of learning and memory with D galactolipins；Confirmed through animal acute toxicity experiment, Morinda officinalis FOS extract safe-dosaging limits are larger, available for fields such as preventing and treating Alzheimer disease drug, health products and food.
Description
Technical field
The present invention relates to the new application of Morinda officinalis FOS extract, and in particular to Morinda officinalis FOS extract exists
Prepare the application in preventing and treating Alzheimer disease drug, health products or food.
Background technology
Alzheimer disease（Alzheimer's disease, AD）It is a kind of nerve of the progress sexual development of onset concealment
System degenerative disease.Clinically with memory disorders, aphasia, appraxia, agnosia, visual space technical ability infringement, perform function obstacle with
And the performance of the generalized dementia such as personality and behavior change is characterized, the cause of disease is unknown so far.The senile dementia cause of disease and pathogenesis are so far
The present is still not clear, and may have multifactor participation, such as old-age group, heredity, metabolism, head injury history, estrogen deficiency.
Research finds there are very many neurons in the enteron aisle of the mankind, the quantity of these neurons is suitable with brain.Enteron aisle
Neurotransmitter that neuron and cerebral neuron are used, metabolic pathway are almost consistent.From enteric nervous member to cerebral nerve
Member, which has, frequently to communicate, than more than the information interchange from brain to enteron aisle.The communication of enteric microorganism and brain is very frequent, learns
Boundary thinks to form one " bacterium intestines brain axle " between enteron aisle and brain, and intestines brain can influence brain, and brain can also influence intestines brain,
It is two-way intercommunication between them.It is main between both to pass through endosecretory pathway, nerve pathway, immunization route and metabolism way
Footpath influences each other.The communication that the factors such as infection in pregnancy, pollutant, pathogen, diet, inflammation can be all had influence between them.I
Can be intervened by the transplanting of probiotics, diet and caprophyl.
Therefore food, prebiotics, probiotics, plant extracts or the medicine that can influence enteric microorganism structure or ecology are found
Thing etc., the treatment for nerve degenerative diseases is a new way.
Morinda officinalis How is the key medicine tonified the kidney and support yang.Early-stage Study shows that it is rich in oligosaccharides composition, and tool kidney tonifying is helped
Sun, antidepression, anti-osteoporosis and raising ability of learning and memory, immunity and endurance isoreactivity.At present both at home and abroad to bar
The research of halberd day FOS is concentrated mainly in terms of major tranquilizer, immunologic adjuvant, but Morinda officinalis FOS is extracted
The research of application of the thing in preventing and treating Alzheimer's disease is also less.
The content of the invention
Preparing preventing and treating Alzheimer disease drug it is an object of the invention to provide Morinda officinalis FOS extract, protecting
Application in strong product or food.
It is preferred that, the safe-dosaging limits of the Morinda officinalis FOS extract are 30mg/kg-500mg/kg.
It is preferred that, the preparation method of the Morinda officinalis FOS extract comprises the following steps：
(1) general-Morinda officinalis fresh medicine material, goes the removal of impurity, appropriate to crush；
(2) distilled water is added to extract, extract solution is concentrated under reduced pressure, and obtains concentrate；
(3) concentrate is added into ethanol precipitation, precipitation is redissolved plus ethanol reprecipitation through water, obtains Morinda officinalis FOS crude product；
(4) Morinda officinalis FOS crude product is redissolved in water, eluted through anion exchange resin, collect eluent, eluent
Add ethanol precipitation after being concentrated under reduced pressure, stand, suction filtration, dry, produce the oligomeric sugar extract of Morinda officinalis.
It is preferred that, the step（2）Extracting mode be heated to reflux, hot submersion or or diacolation in one or more.
It is preferred that, the step（2）Concretely comprise the following steps：Plus 8-10 times measured distilled water, 1-2h, mistake are boiled
Filter, filter residue adds 8-10 times and measures distilled water again, boils 1-2h, filters, and merging filtrate is concentrated under reduced pressure, and obtains concentrate.
It is preferred that, the step（3）Concretely comprise the following steps：Ethanol is added in concentrate, concentration of alcohol is adjusted to 90%,
Refrigeration, stands 2-24h, precipitation is redissolved in hot water, room temperature is cooled to, and adds ethanol, and regulation concentration of alcohol to 90% is refrigerated,
2-24h is stood, must be precipitated, as Morinda officinalis FOS crude product.
The operation of alcohol precipitation can be redissolved, added to precipitation repeatedly by the present invention through water, miscellaneous preferably to remove alcohol-soluble
Matter.
It is preferred that, the step（4）Concretely comprise the following steps：Morinda officinalis FOS crude product is redissolved in hot water, is cooled to
50 DEG C, pH to 4.5-6.5 is adjusted, solution is continuously eluted through D-900 anion exchange resins with 1.0-1.5BV/h flow velocitys, collected
Eluent, 50-70 DEG C is concentrated under reduced pressure into relative density for 1kg：200ml volumes, add ethanol in concentrate, and regulation ethanol is dense
Degree is to 90%, and refrigeration stands 2-24h, stands, suction filtration, dries, produces the oligomeric sugar extract of Morinda officinalis.
The Morinda officinalis FOS extract obtained using above-mentioned preparation method of the invention, it is combined chemistry discriminating, HPLC,
The technology for detection such as LC-MS, as a result show that it mainly contains plain Morinda offcinalis How, this resistance to sugar, 1F- fruit furyl glycosyls resistance to this sugar, inulin (i.e.
(2 → 1) fruit furyl glycosyl sucrose) a variety of oligosaccharide such as type hexa polyose and seven glycan, yield is more than 30%.
The present invention also provides a kind of medicine for preventing and treating Alzheimer's disease, comprising above-mentioned Morinda officinalis FOS extract and
Pharmaceutically acceptable carrier.
The formulation of medicine of the present invention can be tablet, granule, pulvis, capsule or oral liquid etc., its preparation side
Method is prepared using conventional method.
The present invention compared with prior art, has the advantages that：
The present invention is studied through interior animal experiment and found, Morinda officinalis FOS extract can significantly improve A β 1-42 and D- galas
Sugar causes to intend Senile Dementia Model Rats ability of learning and memory；Confirmed through cell and animal acute toxicity experiment, its safe dose model
Enclose big, available for fields such as preventing and treating Alzheimer disease drug, health products and food.
Brief description of the drawings
Fig. 1 is that Morinda officinalis FOS extract causes the HE of aging model rat intestine, brain pathological tissue to contaminate to D- galactolipins
Chromatic graph.
Fig. 2 is Morinda officinalis FOS extract pairCause dementia rats intestines, heart, the shadow of brain pathological tissue
Ring, and in brain tissueHE dyeing and SABC figure with the influence of Tau protein expression levels.
Embodiment
The present invention is further illustrated below by embodiment, following examples are the specific embodiment party of the present invention
Formula, but embodiments of the present invention are not limited by following embodiments.
Morinda officinalis of the present invention is gathered by Guangdong Deqing city Gao Liang towns Morinda officinalis planting base, is identified as Rubiaceae
The dry root of plant Morinda officinalis.Root oblate cylindricality formula cylinder, slightly curved song, length, diameter 1-2cm, surface lark or
Grey yellowish-brown, some micro-strip purples, the vertical wrinkle of tool and the band got deeply stuck in, what is had exposes wood in contracting shape or skin zone's transverse direction dialysis is hung
Portion, shape such as chicken intestines.Matter is tough and tensile, and plane of rupture is uneven, skin zone thickness 5-7mm, lavender, woody part diameter 2-4mm.Gas is micro-, bitter, slightly
It is puckery.
Embodiment 1：The preparation of Morinda officinalis FOS extract
Specifically include following steps：
By Morinda officinalis fresh medicine material, the removal of impurity is gone, it is appropriate to crush；Plus 8 times of amount distilled water, 2h is boiled, is filtered,
Filter residue adds 8 times of amount distilled water again, boils 2h, filters, merging filtrate is concentrated under reduced pressure, and obtains concentrate；Add in concentrate
Enter ethanol, regulation concentration of alcohol to 90%, refrigeration stands 24h, precipitation is redissolved in hot water, room temperature is cooled to, ethanol is added,
Concentration of alcohol is adjusted to 90%, refrigeration stands 24h, must precipitated, as Morinda officinalis FOS crude product；By Morinda officinalis FOS
Crude product is redissolved in hot water, is cooled to 50 DEG C, adjusts pH to 5.0, solution is through D-900 anion exchange resins, with 1.0-1.5BV/h
Flow velocity is continuously eluted, and collects eluent, and 50-70 DEG C is concentrated under reduced pressure into relative density for 1kg：200ml volumes, add in concentrate
Enter ethanol, regulation concentration of alcohol to 90%, refrigeration stands 2-24h, stood, suction filtration, dries, and produces the extraction of Morinda officinalis oligosaccharide
Thing.
By above-mentioned Morinda officinalis FOS extract（OMO）Carry out the test of pesticide effectiveness：
Test example one：Morinda officinalis FOS extract improves D- galactolipins and causes to intend Senile Dementia Model Rats ability of learning and memory
Tested with SPF grades of SD rats, using long-term intraperitoneal injection D- galactolipin method modelings, prepare aging Model of Dementia.Make
After mould, Normal group, model group are respectively with 2 mL/d physiological saline gavages, OMO low dose groups（50 mg/kg/d）, OMO it is high
Dosage group（100 mg/kg/d）, Morinda officinalis FOS extract OMO treatments are given by respective dosage gavage, each group is persistently given
Medicine 8 weeks.After 8 weeks, pass through Morris water mazes（MWM）To assess the Spatial memory ability to rat, 1, table the results are shown in Table
2, Fig. 1.
The oligomeric sugar extract of the Morinda officinalis of table 1. causes aging model rat water maze to test preclinical influence D- galactolipins
As a result（n=6）
The oligomeric sugar extract of the Morinda officinalis of table 2. causes the influence result of aging model rat water maze test platform phase to D- galactolipins
（n=6）
As can be seen from Table 1, the different testing time points of latency test, compared with normal group, model group incubation period is notable
Extension, difference has statistical significance (P<0.05), this experimental model is pointed out to be successfully prepared.Compared with model group, each administration
Group incubation period substantially shortens, and wherein OMO high doses group is better than OMO low dose groups (P<0.05).
As can be seen from Table 2, normal rats are in third quadrant（Quadrant i.e. where platform original）Swimming timeIt is longer than other quadrants, difference has conspicuousness, illustrates that rat is remembered to platform formation.With normal group
Compare, model group is in third quadrant swimming timeIt is appreciably shorter, illustrate that D- galactolipins have infringement big
Mouse memory function；Compared with model group, OMO high doses group is in third quadrant swimming timeIt is obviously prolonged
(P<0.05), prompting Morinda officinalis FOS extract, which has, improves the cause Rats With Memory dysfunction effect of D- galactolipins.
As seen from Figure 1, model group small intestine cells（Intestin）Shrinkage, cell is irregular, and each administration group small intestine is thin
Born of the same parents are more smooth, regular shape, full.Brain stem（Brainstem）In, model group inflammatory cell number is significantly more than each administration
Group, points out administration group to mitigate the inflammatory reaction of cell.Cerebellum（cerebellum）In, compared with model group, each administration group
Cell number showed increased.
Therefore, from the above, it is seen that Morinda officinalis FOS extract, which can improve D- galactolipins, causes plan senile dementia
Rat model ability of learning and memory, reduces tissue inflammation reaction.
Test example two：Morinda officinalis FOS extract improvesCause to intend Senile Dementia Model Rats learning and memory
Ability
Tested, injected using in bilateral hippocampus with SPF grades of SD ratsMethod modeling, prepares aging Model of Dementia.Make
After mould, Normal group, model group are respectively with 2 mL/d physiological saline gavages, OMO low dose groups（50 mg/kg/d）, OMO it is high
Dosage group（100 mg/kg/d）, Morinda officinalis FOS extract OMO treatments are given by respective dosage gavage, each group is persistently given
Medicine 4 weeks.After 4 weeks, pass through Morris water mazes（MWM）To assess the Spatial memory ability to rat, 3, table are the results are shown in Table
4, Fig. 2.
The oligomeric sugar extract pair of the Morinda officinalis of table 3.Cause the preclinical influence knot of dementia rats water maze test
Really（n=6）
The oligomeric sugar extract pair of the Morinda officinalis of table 4.Cause the influence result of Model of Dementia water maze test platform phase（n=
6）
As can be seen from Table 3, the different testing time points of latency test, compared with normal group, model group incubation period is notable
Extension, difference has statistical significance（P<0.05）, point out this experimental model to be successfully prepared.Compared with model group, each administration
Group incubation period substantially shortens, and wherein OMO high doses group is better than OMO low dose groups.
As can be seen from Table 4, in third quadrant（Quadrant i.e. where platform original）Swimming time, compared with model group, respectively
Administration group swimming time significantly extends (P<0.05), the prompting oligomeric sugar extract of Morinda officinalis can improve A β 1-42 and cause to intend old silly
Slow-witted rat model ability of learning and memory.
As seen from Figure 2, compared with model group, in each administration group, small intestine（Intestin）Cell more light is full
It is regular, heart（Heart）Space between cells diminishes, brain（Brain）Cell number showed increased,With the table of Tau albumen
Reduced up to amount, point out the oligomeric sugar extract of Morinda officinalis to improve the function and form of rat tissue's cell, substantially reduce A Er
Ci Haimo disease GAP-associated protein GAPsWith Tau expression.
Therefore, from the above, it is seen that the oligomeric sugar extract of Morinda officinalis, which can improve A β 1-42, causes plan Senlie dementia model
Learning and memory in rats ability, is reducedWith the expression of Tau albumen.
Safety evaluatio：
Toxicity test, according to《Chinese medicine, natural drug peace comment technological guidance's principle》, Morinda officinalis FOS extract dosage model
Enclose for 30mg/kg-500mg/kg.Maximum dosage-feeding 500mg/kg gavages give kunming mice, and Continuous Observation 14 days does not have animal
It is dead.Show that the safe-dosaging limits of Morinda officinalis FOS extract are larger, drug safety.
Application examples：The preparation of granule containing Morinda officinalis FOS extract
Active ingredient：65 parts of Morinda officinalis FOS extract；
Auxiliary material：25 parts of pregelatinized starch, 4 parts of superfine silica gel powder, 6 parts of magnesium stearate.
Preparation technology：By Morinda officinalis FOS extract, pregelatinized starch, superfine silica gel powder, magnesium stearate input mixing
It is well mixed in machine.
Above-mentioned compound is packed into capsule by fully-automatic capsule filler, produced.
Claims (9)
1. application of the Morinda officinalis FOS extract in preventing and treating Alzheimer disease drug, health products or food is prepared.
2. Morinda officinalis FOS extract according to claim 1 is preparing preventing and treating Alzheimer disease drug, health care
Application in product or food, it is characterised in that the safe-dosaging limits of the Morinda officinalis FOS extract are 30mg/kg-
500mg/kg。
3. Morinda officinalis FOS extract according to claim 1 is preparing preventing and treating Alzheimer disease drug, health care
Application in product or food, it is characterised in that the preparation method of the Morinda officinalis FOS extract comprises the following steps：
（1）By Morinda officinalis fresh medicine material, the removal of impurity is gone, it is appropriate to crush；
（2）Plus distilled water is extracted, extract solution is concentrated under reduced pressure, and obtains concentrate；
（3）By concentrate plus ethanol precipitation, precipitation is redissolved plus ethanol reprecipitation through water, obtains Morinda officinalis FOS crude product；
（4）Morinda officinalis FOS crude product is redissolved in water, eluted through anion exchange resin, eluent, eluent is collected
Add ethanol precipitation after being concentrated under reduced pressure, stand, suction filtration, dry, produce the oligomeric sugar extract of Morinda officinalis.
4. Morinda officinalis FOS extract according to claim 1 is preparing preventing and treating Alzheimer disease drug, health care
Application in product or food, it is characterised in that the step（2）The mode of middle extraction is is heated to reflux, in hot submersion or diacolation
One or more.
5. Morinda officinalis FOS extract according to claim 4 is preparing preventing and treating Alzheimer disease drug, health care
Application in product or food, it is characterised in that the step（2）Concretely comprise the following steps：Plus 8-10 times measured distilled water, 1- is boiled
2h, filtering, filter residue adds 8-10 times and measures distilled water again, boils 1-2h, filters, and merging filtrate is concentrated under reduced pressure, and obtains concentrate.
6. Morinda officinalis FOS extract according to claim 1 is preparing preventing and treating Alzheimer disease drug, health care
Application in product or food, it is characterised in that the step（3）Concretely comprise the following steps：Ethanol is added in concentrate, second is adjusted
Determining alcohol is to 90%, and refrigeration stands 2-24h, precipitation is redissolved in hot water, room temperature is cooled to, and adds ethanol, and regulation ethanol is dense
Degree is to 90%, and refrigeration stands 2-24h, must precipitated, as Morinda officinalis FOS crude product.
7. Morinda officinalis FOS extract according to claim 1 is preparing preventing and treating Alzheimer disease drug, health care
Application in product or food, it is characterised in that the step（4）Concretely comprise the following steps：Morinda officinalis FOS crude product is redissolved
In hot water, 50 DEG C are cooled to, pH to 4.5-6.5 is adjusted, solution is through D-900 anion exchange resins, with 1.0-1.5BV/h flow velocitys
Continuous elution, collects eluent, and 50-70 DEG C is concentrated under reduced pressure into relative density for 1kg：200ml volumes, add second in concentrate
Alcohol, regulation concentration of alcohol to 90%, refrigeration stands 2-24h, stands, suction filtration, dries, produces the oligomeric sugar extract of Morinda officinalis.
8. a kind of medicine for preventing and treating Alzheimer's disease, includes Morinda officinalis FOS extract and pharmaceutically acceptable load
Body.
9. a kind of medicine for preventing and treating Alzheimer's disease according to claim 8, it is characterised in that the formulation of the medicine
For tablet, granule, pulvis, capsule or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710411670.6A CN107158012A (en) | 2017-06-05 | 2017-06-05 | Application of the Morinda officinalis FOS extract in preventing and treating Alzheimer disease drug, health products or food is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710411670.6A CN107158012A (en) | 2017-06-05 | 2017-06-05 | Application of the Morinda officinalis FOS extract in preventing and treating Alzheimer disease drug, health products or food is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107158012A true CN107158012A (en) | 2017-09-15 |
Family
ID=59825346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710411670.6A Pending CN107158012A (en) | 2017-06-05 | 2017-06-05 | Application of the Morinda officinalis FOS extract in preventing and treating Alzheimer disease drug, health products or food is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107158012A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107811991A (en) * | 2017-11-27 | 2018-03-20 | 广东省微生物研究所（广东省微生物分析检测中心） | The preparation method of the enteric coated preparations of the FOS containing Morinda officinalis and the preparation being prepared |
| CN107812019A (en) * | 2017-11-27 | 2018-03-20 | 广东省微生物研究所（广东省微生物分析检测中心） | A kind of probiotics of the FOS containing Morinda officinalis and its production and use |
| CN113278081A (en) * | 2021-04-25 | 2021-08-20 | 广州医科大学附属第五医院 | Morinda officinalis oligosaccharide and preparation method and application thereof |
| GB2590624B (en) * | 2019-12-20 | 2023-08-30 | Green Bioactives Ltd | Composition comprising one or more fructooligosaccharide(s) and L-theanine |
-
2017
- 2017-06-05 CN CN201710411670.6A patent/CN107158012A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 陈地灵: "巴戟天低聚糖巴戟甲素抗老年痴呆药效及作用机制研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
| 陈地灵等: "巴戟天低聚糖对Aβ25-35致拟痴呆模型大鼠学习记忆障碍的影响", 《中国药理学通报》 * |
| 陈地灵等: "巴戟天低聚糖对Aβ25-35致拟痴呆模型大鼠的保护作用", 《中国中药杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107811991A (en) * | 2017-11-27 | 2018-03-20 | 广东省微生物研究所（广东省微生物分析检测中心） | The preparation method of the enteric coated preparations of the FOS containing Morinda officinalis and the preparation being prepared |
| CN107812019A (en) * | 2017-11-27 | 2018-03-20 | 广东省微生物研究所（广东省微生物分析检测中心） | A kind of probiotics of the FOS containing Morinda officinalis and its production and use |
| CN107812019B (en) * | 2017-11-27 | 2021-01-29 | 广东省微生物研究所（广东省微生物分析检测中心） | Microecological preparation containing morinda officinalis fructo-oligosaccharide and preparation method and application thereof |
| GB2590624B (en) * | 2019-12-20 | 2023-08-30 | Green Bioactives Ltd | Composition comprising one or more fructooligosaccharide(s) and L-theanine |
| CN113278081A (en) * | 2021-04-25 | 2021-08-20 | 广州医科大学附属第五医院 | Morinda officinalis oligosaccharide and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107158012A (en) | Application of the Morinda officinalis FOS extract in preventing and treating Alzheimer disease drug, health products or food is prepared | |
| US20080112967A1 (en) | Process for Refining Ganoderma Spore Polysacchoride | |
| AU2004200624B2 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same | |
| CN106943423A (en) | The polysaccharide composition acted on regulating intestinal canal Bacterial community and its application | |
| CN105147717B (en) | Application of the Fuscoporia obliqua polysaccharide component in chronic pancreatitis is prevented and treated | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| CN107412254B (en) | Application of anoectochilus formosanus polysaccharide extract | |
| CN106963777A (en) | A kind of preparation method and applications of " scutelloside jamaicin " compound | |
| CN102935100A (en) | Preparation method and applications of queen lagerstroemia folium apocyni veneti general flavones | |
| CN102188519B (en) | Chinese medicinal compound preparation for treating hepatic fibrosis and preparation method thereof | |
| CN111568949A (en) | Application of mulberry extract in preparation of medicine for regulating animal intestinal flora | |
| CN100444849C (en) | New use of tribulus terrestris extraction | |
| CN101274013B (en) | Prescription medicine for curing senile dementia and preparation | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN107266599B (en) | Flammulina velutipes, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| CN103191175B (en) | Diarrhoea-stopping traditional Chinese medicine composition, capsule and application thereof | |
| CN101785816B (en) | Grass-leaved sweetflag extract, medicine composition with grass-leaved sweetflag extract, preparation method and application thereof | |
| CN100545163C (en) | Traditional Chinese medicine active ingredient compound for preventing and treating senile dementia and preparation and application thereof | |
| CN1687092A (en) | General glycoside extractive of xanthium and preparation method | |
| CN113117036A (en) | A medicine containing green tea extract for treating fatty liver and its preparation method | |
| CN113730466A (en) | Preparation method and application of blackberry extract | |
| CN106928376A (en) | The separation method of skunk bush polysaccharide and its application | |
| CN112336764A (en) | Traditional Chinese medicine composition for resisting oxidation and enhancing immunity and preparation method and application thereof | |
| CN106265717A (en) | Dicliptera chinensis polysaccharide application in preparation preventing and treating diabetes medicament or health product | |
| CN111053819A (en) | Traditional Chinese medicine composition extract and application thereof in preparation of protein expression regulator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170915 |
|
| RJ01 | Rejection of invention patent application after publication |